Scientist, Preclinical Ophthalmology
SpliceBio3w ago
Barcelona
The English-language job board for Spain
87,000+ live jobsSpliceBio
SpliceBio is a clinical-stage biotechnology company developing gene therapies using its proprietary Protein Splicing platform, which enables the delivery of large therapeutic genes.
2 open
- Locations
- Barcelona, Barcelona, Spain (Hybrid)
- Level
- Mid-Level for 2 of 2
- Locations
- Barcelona, Barcelona, Spain (Hybrid)
- Level
- Mid-Level for 2 of 2
2 jobs
Sorted by
Regulatory Affairs Manager
SpliceBio1mo ago
Hybrid in Barcelona
About the company
SpliceBio is a clinical-stage biotechnology company developing gene therapies using its proprietary Protein Splicing platform, which enables the delivery of large therapeutic genes. The company is headquartered in Barcelona, Spain, and has raised over $200 million from top-tier investors including Novartis Venture Fund and Sanofi Ventures. Its lead program targets Stargardt disease, a genetic eye disorder, and is currently in clinical trials.
For International Professionals
- Headquartered in Barcelona's Parc Científic, a major science park, offering a vibrant research environment.
- The company has international offices in Ireland and the Netherlands, indicating a global footprint.
- As a clinical-stage biotech, it offers opportunities in R&D, clinical operations, and regulatory affairs.
- The team includes professionals from diverse backgrounds, suggesting an international work culture.
- The company emphasizes career development and team-building activities, as stated on its careers page.
Offices in Spain
Company History
SpliceBio is a clinical-stage genetic medicines company founded in 2014 (formerly ProteoDesign) and headquartered in Barcelona, Spain. It leverages a proprietary Protein Splicing platform based on intein technology developed at Princeton University to develop next-generation gene therapies for large-gene diseases. In June 2025, the company closed a $135 million Series B financing to advance its lead program SB-007 for Stargardt disease and expand its pipeline.